{"id":"lubeluzole","rwe":[{"pmid":"40652670","year":"2025","title":"Hunting for lubeluzole analogues as antimyotonic agents with reduced cardiac liability.","finding":"","journal":"European journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"38367265","year":"2024","title":"Drug Repositioning for Ovarian Cancer Treatment: An Update.","finding":"","journal":"Anti-cancer agents in medicinal chemistry","studyType":"Clinical Study"},{"pmid":"36431971","year":"2022","title":"Lubeluzole Repositioning as Chemosensitizing Agent on Multidrug-Resistant Human Ovarian A2780/DX3 Cancer Cells.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"34463026","year":"2022","title":"Intra-arterial combination therapy for experimental acute ischemic stroke.","finding":"","journal":"Clinical and translational science","studyType":"Clinical Study"},{"pmid":"33074530","year":"2021","title":"Lubeluzole: from anti-ischemic drug to preclinical antidiarrheal studies.","finding":"","journal":"Pharmacological reports : PR","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Neuroprotective Agents","category":"pharmacology"},{"label":"Protective Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["lubeluzole"],"offLabel":[],"synonyms":["lubeluzole"],"timeline":[],"aiSummary":"Lubeluzole is a small molecule. Its mechanism of action is not specified in the provided information.","approvals":[],"ecosystem":[],"mechanism":{"target":"Calmodulin, Sodium channel protein type 2 subunit alpha","modality":"Small Molecule","explanation":"Imagine your brain cells communicating with each other through electrical signals. Lubeluzole helps regulate these signals by affecting the channels that allow them to flow in and out of the cells. This can help restore balance to the brain's communication system.","oneSentence":"Lubeluzole is thought to work by modulating ion channels and neurotransmitter release.","technicalDetail":"Lubeluzole is believed to act as a modulator of ion channels, specifically affecting the flow of potassium and sodium ions, which can influence neurotransmitter release and neuronal excitability."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3328","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LUBELUZOLE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:25:44.828396","biosimilars":[],"competitors":[{"drugName":"etidocaine","drugSlug":"etidocaine","fdaApproval":"1976-08-30","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"lacosamide","drugSlug":"lacosamide","fdaApproval":"2008-10-28","patentExpiry":"Jun 5, 2040","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"lamotrigine","drugSlug":"lamotrigine","fdaApproval":"1994-12-27","patentExpiry":"May 29, 2040","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"mibefradil","drugSlug":"mibefradil","fdaApproval":"1997-08-01","relationship":"same-target"},{"drugName":"phenytoin","drugSlug":"phenytoin","fdaApproval":"1953-01-06","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"pimozide","drugSlug":"pimozide","fdaApproval":"1984-07-31","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"topiramate","drugSlug":"topiramate","fdaApproval":"1996-12-24","patentExpiry":"Nov 16, 2027","patentStatus":"Patent protected","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"lubeluzole","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"etidocaine","brandName":"etidocaine","genericName":"etidocaine","approvalYear":"1976","relationship":"same-target"},{"drugId":"lacosamide","brandName":"lacosamide","genericName":"lacosamide","approvalYear":"2008","relationship":"same-target"},{"drugId":"lamotrigine","brandName":"lamotrigine","genericName":"lamotrigine","approvalYear":"1994","relationship":"same-target"},{"drugId":"mibefradil","brandName":"mibefradil","genericName":"mibefradil","approvalYear":"1997","relationship":"same-target"},{"drugId":"phenytoin","brandName":"phenytoin","genericName":"phenytoin","approvalYear":"1953","relationship":"same-target"},{"drugId":"pimozide","brandName":"pimozide","genericName":"pimozide","approvalYear":"1984","relationship":"same-target"},{"drugId":"topiramate","brandName":"topiramate","genericName":"topiramate","approvalYear":"1996","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"V2SIB71583","INN_ID":"7198","UMLSCUI":"C0385965","ChEMBL_ID":"CHEMBL281724","KEGG_DRUG":"D04789","PUBCHEM_CID":"65998","MESH_SUPPLEMENTAL_RECORD_UI":"C097722"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"21.6 hours","clearance":"1.7 mL/min/kg","fractionUnbound":"0.003%","volumeOfDistribution":"2.6 L/kg"},"publicationCount":94,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov 5","pmid":"40652670","title":"Hunting for lubeluzole analogues as antimyotonic agents with reduced cardiac liability.","journal":"European journal of medicinal chemistry"},{"date":"2024","pmid":"38367265","title":"Drug Repositioning for Ovarian Cancer Treatment: An Update.","journal":"Anti-cancer agents in medicinal chemistry"},{"date":"2022 Nov 15","pmid":"36431971","title":"Lubeluzole Repositioning as Chemosensitizing Agent on Multidrug-Resistant Human Ovarian A2780/DX3 Cancer Cells.","journal":"Molecules (Basel, Switzerland)"},{"date":"2022 Jan","pmid":"34463026","title":"Intra-arterial combination therapy for experimental acute ischemic stroke.","journal":"Clinical and translational science"},{"date":"2021 Feb","pmid":"33074530","title":"Lubeluzole: from anti-ischemic drug to preclinical antidiarrheal studies.","journal":"Pharmacological reports : PR"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"LUBELUZOLE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}